Windsor Capital Management LLC Invests $671,000 in Astrazeneca Plc $AZN

Windsor Capital Management LLC bought a new stake in shares of Astrazeneca Plc (NYSE:AZN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,539 shares of the company’s stock, valued at approximately $671,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Triumph Capital Management purchased a new stake in Astrazeneca in the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new position in Astrazeneca during the fourth quarter valued at $26,000. Mascoma Wealth Management LLC purchased a new position in Astrazeneca during the first quarter valued at $26,000. Roxbury Financial LLC acquired a new stake in shares of Astrazeneca in the second quarter valued at about $29,000. Finally, Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca in the fourth quarter valued at about $30,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the subject of a number of research reports. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. HSBC cut Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Stock Performance

NYSE AZN opened at $161.28 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. The stock’s fifty day moving average is $176.34 and its two-hundred day moving average is $187.12. The firm has a market capitalization of $250.12 billion, a P/E ratio of 24.11, a price-to-earnings-growth ratio of 1.39 and a beta of 0.26. Astrazeneca Plc has a fifty-two week low of $145.79 and a fifty-two week high of $212.71.

Astrazeneca (NYSE:AZN) last issued its earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The business had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. During the same period last year, the company earned $2.17 EPS. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. On average, research analysts anticipate that Astrazeneca Plc will post 10.22 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.